Management

Bart Henderson, MBA
President, Chief Executive Officer, and Co-Founder
Mr. Henderson is Chief Executive Officer and a co-founder of Torque. He previously was President and Founder of Rhythm and its subsidiary, Motus (acquired by Allergan), with responsibility for business development, finance, marketing, and manufacturing operations. Prior to that, he was Entrepreneur-in-Residence at MPM Capital; Chief Business Officer of Radius, where he was a founding employee; Head of Sales and Marketing at Vertex; Head of Business Development at Microbia (now Ironwood Pharmaceuticals); and also held marketing management positions at Amgen and Merck. Mr. Henderson received an MBA from Dartmouth’s Tuck School of Business and a BA from Amherst College.

Thomas Lars Andresen, PhD
Chief Scientific Officer and Co-Founder
Dr. Andresen is Chief Scientific Officer and a co-founder at Torque. Prior to joining Torque, he held positions at the prestigious Technology University of Denmark (DTU), including Professor and Head of Department at DTU Nanotech and Head of the DTU Center for Nanomedicine and Theranostics. Dr. Andresen has founded several cancer medical technology and biotechnology companies in Europe focused on chemotherapy and radiation therapy and has pioneered multiple technologies that are in ongoing clinical trials. Dr. Andresen has more than 20 years of research and development experience in the fields of organic chemistry, biophysics, advanced materials engineering, and cancer biology and is an author on more than 100 research or review articles and multiple patent applications.

Becker Hewes, MD
Chief Medical Officer
Dr. Hewes is Chief Medical Officer of Torque. He has more than 10 years of industry experience, most recently serving as an Executive Medical Director at Novartis Institute for Biomedical Research, where he was responsible for a wide array of clinical and preclinical immuno-oncology compounds as well as the early clinical development of ribociclib in breast cancer. Dr. Hewes has held positions within early oncology clinical development at both Genzyme and AstraZeneca. At Wyeth Oncology, he was responsible for the supplemental NDA filing for Torisel in Mantle Cell Lymphoma as well as the phase 1-3 program for bosutinib that resulted in FDA approval in chronic myeloid leukemia. Prior to joining industry, Dr. Hewes’ research focused on preclinical models of anti-tumor immunity at the Emory-Yerkes Vaccine Center.

Sok Cheng Soh, MBA
Chief Financial Officer
Ms. Soh is Chief Financial Officer of Torque. She brings more than 25 years of experience in finance and public accounting to her position as Chief Financial Officer of Torque, including treasury, controllership, operations, and financial planning. Prior to joining Torque, Ms. Soh was Vice President, Treasury and Tax at Bioverativ, a biotechnology company acquired in 2018 by Sanofi, where she established and built the company’s tax and treasury capabilities. Previously, she was Assistant Treasurer at Boston Scientific, where she led capital market initiatives, financial risk management, and treasury operations. She holds an MBA from the University of Chicago Booth School of Business and a Bachelor of Accounting from the University of Singapore.

Jennifer Camacho, JD
Chief Legal Officer
Ms. Camacho is the Chief Legal Officer at Torque. Previously, she was the Chief Legal Officer for Gen9 until its acquisition by Ginkgo Bioworks in January 2017. She is a member of the Patent Public Advisory Committee to the U.S. Patent and Trademark Office, appointed by the U.S. Secretary of Commerce in 2015. Prior to joining Gen9, Ms. Camacho was a partner in Greenberg Traurig, LLP, and Proskauer Rose, LLP. She holds a JD from Boston College Law School.

Tapan Maniar
Vice President of Clinical Development
Dr. Maniar is Vice President of Clinical Development at Torque. Previously, he was Senior Director of Clinical Development at Atara Biotherapeutics, where he led clinical development of several allogeneic T cell therapy programs for oncology and autoimmune diseases. Prior to Atara, Dr. Maniar held several leadership positions at Amgen, including Global Development Lead for blinatumomab (Blincyto), a first-in-class bi-specific T-cell engager that received FDA breakthrough designation and was approved for relapsed/refractory acute lymphocytic leukemia. Dr. Maniar completed his Oncology and Hematology Fellowship as well as Internal Medicine Residency and received his MD from the University of Pennsylvania.

Eden Fucci
Vice President of Biologics Manufacturing
Mr. Fucci is Vice President of Biologics Manufacturing at Torque. He was previously Senior Director of CMC at Aeglea Biotherapeutics where he led process development, manufacturing, and supply chain for clinical studies. Prior to that, he was Senior Director of Drug Product Manufacturing and Supply Chain at Aldeyra Therapeutics, and he also held manufacturing and supply chain management positions at Alexion, Synageva, Eli Lilly, and Imclone. Mr. Fucci has an MS in Biotechnology Enterprise and Entrepreneurship from The Johns Hopkins University and a BS in Biology from Pennsylvania State University.

Karsten Sauer, PhD
Vice President of Immunology
Dr. Sauer is Vice President of Immunology at Torque. Prior to joining Torque, he was Director of Cancer Immunology at Pfizer, where he developed a portfolio of cancer immuno-therapeutics. He has an adjunct appointment at The Scripps Research Institute in La Jolla, California, where he identified important functions for soluble inositol phosphate molecules in hematopoiesis and immune system as well as mechanisms through which oncogenic kinases can become drug-resistant. Before joining Scripps, Dr. Sauer was a Principal Investigator at the Genomics Institute of the Novartis Research Foundation, where he used genetic, functional genomic, and chemogenomic approaches to identify novel therapeutic targets for immune disorders. Dr. Sauer has a PhD in Biochemistry from the University of Tübingen.

Ana Radeljevic, MBA, CFA, CPA
Vice President, Head of Business Operations
Ms. Radeljevic is Vice President, Head of Business Operations at Torque. She has more than 20 years of finance, business development, and operations experience. Prior to joining Torque, she was founder and CEO of Adventus Partners, a life sciences strategy and business development advisory firm. Previously, she was Vice President of Financial Planning & Analysis at PerkinElmer and, before that, she held several management positions at Sanofi and Genzyme, including Global Head of Business Planning and Business Development for Biosurgery and Corporate Finance, where she assisted in the divestment of Genzyme’s Genetic Testing, Diagnostics, and Pharmaceuticals businesses ($1.2 billion) and the negotiations leading to Sanofi’s acquisition of Genzyme. Ms. Radeljevic started her career with Deloitte’s Audit and Valuation practices advising clients on M&A transactions. Prior to her career in the life sciences, she was a professional tennis player, reaching world ranking of top 200. Ms. Radeljevic received an MBA from Syracuse University and holds CPA and CFA designations.

Back to Top